David H. Mack, Ph.D.
Co-Founder, President & CEO
Prior to co-founding PMV Pharma with biologists Arnold Levine and Thomas Shenk, Dr. Mack was a general partner at Alta Partners from 2002 to 2013. His first investment was Angiosyn (acquired by Pfizer in 2005) where he was a Director and CEO. Prior to Alta, Dr. Mack co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003).
From 1994 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) Invention Group at Cetus (now Novartis) in the mid 1980s. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 26 issued US patents. Dr. Mack was an American Cancer Society Postdoctoral Fellow in microbiology and immunology at Stanford University School of Medicine. He received his Ph.D. from the University of Chicago, where he was a Howard Hughes Fellow in Molecular Genetics and Cell Biology, and a B.A. in Molecular Biology from the University of California, Berkeley.
Chief Operating Officer and Chief Financial Officer
Prior to joining PMV Pharma, Mr. Kung was a Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer at Celgene Cellular Therapeutics (CCT). Over four and a half years, he led the formation of a strategic long range plan for CCT, multiple transactions and a team that managed Celgene’s alliance portfolio of over 100 collaborations, equity investments and company integrations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group. He worked on various transactions including public and private financings, mergers, acquisitions, spin-outs and other financial advisory engagements.
From 2004 to 2007, he served at Amgen as a co-founder of the Alliance Management group, and also served as the deal lead on multiple acquisitions as part of the Corporate Development group. Mr. Kung was also part of the Business and Corporate Development group at Genentech. He worked on several transactions, including leading the spin-out of Tercica (acquired by Ipsen), and co- led the formation of the Genenfund, Genentech’s first Corporate Venture Capital Fund. He received his MBA from Harvard Business School, and his A.B. in Biology and A.B in International Relations with honors from Brown University.
Leila Alland, M.D.
Chief Medical Officer
Dr. Alland brings over 25 years of experience in oncology to the leadership of PMV Pharma. Dr. Alland, a pediatric hematologist-oncologist and accomplished physician-scientist, has been working in the biopharmaceutical industry since 2001 to bring novel therapies to patients. Dr. Alland has held leadership positions at Affimed, Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb, Novartis, and Schering-Plough, where she worked on a broad range of oncology products from early to late stage development and contributed to multiple successful drug approvals. Dr. Alland obtained her medical degree from New York University School of Medicine, and her B.A. in Biology from the University of Pennsylvania. She completed her residency in Pediatrics at The Children’s Hospital of Philadelphia, and her fellowship in Pediatric Hematology/Oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center. From 1994 to 2000, Dr. Alland served as Assistant Professor of Pediatrics at Albert Einstein College of Medicine where she was awarded the James S. McDonnell Foundation Scholar Award and pursued basic cancer research while also caring for children with cancer. Dr. Alland sits on the Scientific Advisory Council of Columbia University's Center for Radiological Research and serves as a reviewer for the Cancer Prevention and Research Institute of Texas.
Deepika Jalota, Pharm.D.
Senior Vice President, Head of Regulatory Affairs
Prior to joining PMV Pharma, Dr. Jalota was Vice President, Head of Global Regulatory Strategy, Oncology I at Bayer HealthCare Pharmaceuticals where she was responsible for overseeing the development of global regulatory strategies for several early and late stage oncology projects, including Xofigo®, VITRAKVI® and darolutamide. From 2014-2016 at Bayer, she was responsible for overseeing the development of global regulatory strategies in Ophthalmology and Dermatology, including Eylea®.
Prior to working at Bayer for 12 years, Dr. Jalota was employed with Sanofi-Aventis, Forest Laboratories and Procter and Gamble Pharmaceuticals within various roles across drug development.
Dr. Jalota received her Pharm.D. from University of Florida, College of Pharmacy, and her B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy.
Binh Vu, Ph.D.
Vice President, Chemistry
Prior to joining PMV Pharma as Director of Research, Dr. Vu was a Research Leader at Roche Nutley where he spent 15 years working in small molecule oncology drug discovery. While at Roche, Dr. Vu was a key contributor to the discovery and development of Nutlins, small molecule MDM2 antagonists which target the p53 pathway. He has extensively published on p53 biology and drug discovery, and is an inventor on 14 issued US patents.
Dr. Vu received a Ph.D. in Chemistry from the University of California, Los Angeles, and completed an NIH Postdoctoral Fellowship at the University of Texas at Austin. He received a B.S. in Chemistry from the University of California, Irvine.
Thomas Davis, Ph.D.
Vice President, Biology
Dr. Davis joined PMV Pharma as Vice President of Biology after 13 years at PTC Therapeutics where he was responsible for building and developing the Oncology portfolio. While at PTC, Dr. Davis' group developed three drug candidates, two of which (PTC299 and PTC596) have entered clinical trials. His industry experience began at Pharmacia Corporation, where he led a team tasked with expanding the selective COX2 inhibitor celecoxib (Celebrex, Pfizer) into the oncology arena. Dr. Davis has co-authored over 20 manuscripts and is an inventor on over 10 issued US patents.
Dr. Davis received a Ph.D. in Microbiology and Immunology from the University of Kentucky, and completed a Postdoctoral Fellowship at the University of Wisconsin, Madison. He received a B.S. in Microbiology from Iowa State University.
Melissa Dumble, Ph.D.
Vice President, Pharmacology and Translational Medicine
Prior to joining PMV Pharma, Dr. Dumble was a Research Leader at Bristol-Myers Squid (BMS, Lawrenceville site) developing small molecules to regulate tumor intrinsic targets that may sensitize cancers to immuno-oncology agents. Before her tenure at BMS she worked at PTC Therapeutics and Enzon Pharmaceuticals leading drug discovery projects in oncology, infectious disease and genetic disorders from lead optimization to clinical trials. Dr. Dumble began her career at GSK Oncology, training as a pharmacologist and working on many of the marketed kinase inhibitors (e.g. VotrientTM, MekinistTM, TafinlarTM). In addition, she led the team of scientists developing an oral Akt inhibitor to clinical trials. Dr. Dumble has co-authored over 20 manuscripts and is an inventor on 5 issued patents.
Dr. Dumble received a Ph.D. in Cell and Molecular Biology from the University of Western Australia, and completed a Postdoctoral Fellowship at Baylor College of Medicine, Houston. Her studies were based on understanding the role of p53 in stem cell dynamics, cancer and aging. She received a B.S. in Biochemistry and Human Biology from the University of Western Australia.